Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Mark A. Forman"'
Autor:
Jeanine R. Jarnes, Caroline A. Hastings, Can H. Ficicioglu, Debra-Lynn Day-Salvatore, Roberto Giugliani, Julien Baruteau, Chester B. Whitley, Michal Inbar-Feigenberg, Geneviève Bernard, Fatih S. Ezgü, Yan G. Ni, Michelle Miller, Michael H. Gelb, Pruthvi Nagilla, Rose Johnstone, Patricia Elsasser, Elizabeth Cunningham, Victoria Ballard, Thomas F. Haws, Mark S. Forman, David A. Weinstein
Publikováno v:
Molecular Genetics and Metabolism. 138:107169
Autor:
Samiah A. Al-Zaidy, Nicole I. Wolf, Simon Jones, Eric J. Mallack, Amy Waldman, Jennifer P. Rubin, Joshua L. Bonkowsky, Adi Aran, Yan G. Ni, Pruthvi Nagilla, Dan Donahue, Roberto Giugliani, Mark S. Forman, Geneviève Bernard
Publikováno v:
Molecular Genetics and Metabolism. 138:106999
Autor:
Amanda J. Myers, Alan M. Pittman, Alice S. Zhao, Kristen Rohrer, Mona Kaleem, Lauren Marlowe, Andrew Lees, Doris Leung, Ian G. McKeith, Robert H. Perry, Chris M. Morris, John Q. Trojanowski, Christopher Clark, Jason Karlawish, Steve Arnold, Mark S. Forman, Vivianna Van Deerlin, Rohan de Silva, John Hardy
Publikováno v:
Neurobiology of Disease, Vol 25, Iss 3, Pp 561-570 (2007)
Previously we have shown that the H1c haplotype on the background of the H1 clade of haplotypes at the MAPT locus is associated with increased risk for progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Alzheimer’s disease (A
Externí odkaz:
https://doaj.org/article/8d634a24426e480a820cfa3b11293a36
Autor:
Julie A. Stone, Mark S. Forman, Marissa F. Dockendorf, John Palcza, Lei Ma, Michael Tanen, Marianne van Vugt, Matthew D. Troyer, Huub Jan Kleijn, Kazuko Masuo, Peter Hodsman, Jack Tseng, K Chris Min
Publikováno v:
Clinical Pharmacology & Therapeutics. 105:1234-1243
β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is required for the production of β-amyloid (Aβ) peptides and is considered a potential treatment target for Alzheimer's disease (AD). To support Japan's participation in the global clinic
Autor:
Abbas Walji, Kim Serdons, Aubrey Stoch, Cyrille Sur, Eric D. Hostetler, Sofie Celen, Jeffrey L. Evelhoch, Mathieu Vandenbulcke, Kerry Riffel, Idriss Bennacef, Arie Struyk, Talakad G. Lohith, Mark S. Forman, Kuenhi Tsai, Ruben Declercq, Guy Bormans, Tom Reynders, Cristian Salinas, Koen Van Laere, N. Florestina Telan-Choing, Rik Vandenberghe
Publikováno v:
Journal of Nuclear Medicine. 60:107-114
18F-MK-6240 (18F-labeled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective, subnanomolar-affinity PET tracer for imaging neurofibrillary tangles (NFTs). Plasma kinetics, brain uptake, and preliminary quantitative
Autor:
John Palcza, Matthew D. Troyer, Marissa F. Dockendorf, Jack Tseng, Mark S. Forman, Julie A. Stone, Brittany Walker, Dennis Swearingen
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 12, Iss 5, Pp 545-555 (2019)
Clinical and Translational Science, Vol 12, Iss 5, Pp 545-555 (2019)
β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is required for the production of β-amyloid peptides, which are implicated in the etiology of Alzheimer's disease. The safety and pharmacokinetics of the BACE1 inhibitor verubecestat have p
Autor:
Mark S. Forman, Peter Orth, Ulrich Iserloh, Yusheng Wu, Hongwu Wang, William J. Greenlee, Reshma Kuvelkar, Xia Chen, Jack D. Scott, John Meredith, Lana M. Rossiter, Lynn A. Hyde, Robert A. Hodgson, Andrew Stamford, Julie A. Stone, Irina Kazakevich, Ganfeng Wang, Eric M. Parker, Eric J. Gilbert, Kathleen Cox, Corey O. Strickland, Sarah W. Li, Meagan Slater, Qin Jiang, Johannes H. Voigt, Hong Mei, Andrew Brunskill, Matthew E. Kennedy, Misiaszek Jeffrey A, Jared N. Cumming
Publikováno v:
Journal of Medicinal Chemistry. 59:10435-10450
Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the
Autor:
Thomas Edwards, Laurence J. Thorpe, Michael F. Korpi, Keith Graham, Martin P. Feldman, Peter G. M. Centen, Mark L. Forman, Fumiaki Usui, Anna Dining, Charles Poynton, Ryuhei Kamata, Johannes Steurer, Jeroen Hubert Stessen, Daniel Teruggi, Eric Wenocur, Douglas Trumbull, Jyotsna Kadimi, Neil A. Shaw, Elizabeth DoVale, Paul Kellar, David Kuther, David J. Bancroft, Rutger Nijland, Peter Symes, Mona Smothers, R. Norman Hurst, James Cameron
Publikováno v:
SMPTE Motion Imaging Journal. 125:14-21
Autor:
Mark S. Forman, Maria C. Carrillo, Christopher Randolph, David S. Knopman, John R. Sims, David S. Miller, Lisa J. Bain, Maria Isaac, Nicholas Kozauer, Niklas Mattsson, Ronald C. Petersen, Susan DeSanti, Eric E. Smith, James Hendrix, Gil D. Rabinovici
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer's & dementia (New York, N. Y.), vol 3, iss 1
Alzheimer's & dementia (New York, N. Y.), vol 3, iss 1
Dementia is often characterized as being caused by one of several major diseases, such as Alzheimer's disease (AD), cerebrovascular disease, Lewy body disease, or a frontotemporal degeneration. Failure to acknowledge that more than one entity may be
Autor:
Mark A. Forman, Caitlin A. Moran, James E. Hall, Don E. Pivonka, Joseph P. Herres, John P. McCauley, Steven Wesolowski
Publikováno v:
The Journal of Organic Chemistry. 81:6862-6866
The diiodobinorsnoutane, bi(5-iodopentacyclo[4.3.0.0(2,4).0(3,8).0(5,7)]non-4-yl) (5), exists in a sterically hindered gauche conformation rather than an anti or an averaged (freely rotating) C2v structure. Density functional theory (DFT) predictions